Work

Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series

Year: 2025

Type: article

Abstract: Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms1. Therapies include chemotherapy or immunotherapy2-4 though stem cell transplantation (SCT) is the best consolidative approach in eligible patients5. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN.

Source: International Journal of Hematology-Oncology and Stem Cell Research

DOI: 10.18502/ijhoscr.v19i1.17829

Authors: Esra Cengiz, Muruvvet Seda Aydin, Ahmet K Gunes, Funda Ceran, Simten Dagdas, Gulsum Ozet

Institutions: Şanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi, Ankara Bilkent City Hospital, Ankara Etlik City Hospital

Language: English

Topic: Histiocytic Disorders and Treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4407347026

FWCI: 0.548

Cites:

Cited by: 1

Related to: 10